Menu

Blog

Archive for the ‘genetics’ category: Page 468

Apr 4, 2016

CRISPR Dispute Raises Bigger Patent Issues That We’re Not Talking About

Posted by in categories: bioengineering, biotech/medical, genetics, law, robotics/AI

Good read; and highlights fair arguments around science and technology innovations and their patents. CRISPR was highlighted; however, the same can be applied to things like AI. What happens when a Humanoid robot owned by an investment bank innovates and develops new technology for Wall Street? The humanoid robot was (in this example) created by Microsoft; however, is owned by a Goldman Sachs. Who truly owns this new technology innovation? Could we see Goldman Sachs owning 70% of the patent & Microsoft owning 30%?


The worlds of science, technology and patent law eagerly await the U.S. government’s decision on who deserves patents on what many have referred to as the biotechnology invention of the century: the CRISPR/Cas9 gene-editing technique.

Scientists hail CRISPR/Cas9 as more accurate and efficient than other, now-traditional genetic engineering methods. As a result, CRISPR has generated worldwide debate about how it could accelerate the manipulation of plants, animals and even human beings at the molecular level. That some DNA modifications can be passed on to future generations raises particular concern.

Continue reading “CRISPR Dispute Raises Bigger Patent Issues That We’re Not Talking About” »

Apr 2, 2016

Of mice and old men: is the elixir of youth finally coming of age?

Posted by in categories: bioengineering, biotech/medical, genetics, life extension, neuroscience

Preliminary work suggests that T-cells, which normally target disease, can be genetically engineered to target senescent cells in a wide range of tissues. In future, an infusion of GM blood every few years might be able to keep you going indefinitely (assuming some major advances in treating cancer, Alzheimer’s and heart disease). At which point, the question might be less: “How long have I got?” and more: “How long do you fancy sticking around?”


American scientists have coined the term ‘senolytics’ to describe a new class of drugs designed to delay the ageing process by clearing out doddery cells.

Read more

Apr 2, 2016

Europe gives green light to first gene therapy for children

Posted by in categories: biotech/medical, genetics

LONDON The world’s first life-saving gene therapy for children, developed by Italian scientists and GlaxoSmithKline, has been recommended for approval in Europe, boosting the pioneering technology to fix faulty genes.

The European Medicines Agency (EMA) said on Friday it had endorsed the therapy, called Strimvelis, for a tiny number of children with ADA Severe Combined Immune Deficiency (ADA-SCID) for whom no matching bone marrow donor is available.

Around 15 children a year are born in Europe with the ultra-rare genetic disorder, which leaves them unable to make a type of white blood cell. They rarely survive beyond two years unless their immune function is restored with a suitable bone marrow transplant.

Read more

Mar 31, 2016

On/off button for passing along epigenetic ‘memories’ to our children discovered

Posted by in categories: biotech/medical, genetics

The duration of epigenetic responses underpinning transgenerational inheritance is determined by an active mechanism relying on the production of small RNAs and modulation of RNAi factors, dictating whether ancestral RNAi responses would be memorized or forgotten (credit: Leah Houri-Ze’evi et al./Cell)

According to epigenetics — the study of inheritable changes in gene expression not directly coded in our DNA — our life experiences may be passed on to our children and our children’s children. Studies on survivors of traumatic events have suggested that exposure to stress may indeed have lasting effects on subsequent generations.

But exactly how are these genetic “memories” passed on?

Continue reading “On/off button for passing along epigenetic ‘memories’ to our children discovered” »

Mar 29, 2016

WIRB-Copernicus Group Establishes WCG Gene Therapy Advisory Board

Posted by in categories: bioengineering, biotech/medical, genetics, health

1st of many steps in the gene editing oversight.


PRINCETON, N.J., March 29, 2016 /PRNewswire/ — WIRB-Copernicus Group® (WCG™), one of the world’s leading providers of solutions that measurably improve the quality and efficiency of clinical research, today announced that it has assembled a team of world-renowned experts to advise the company regarding the latest advances in gene therapy research. The WCG Gene Therapy™ Advisory Board will convene today in Princeton, NJ.

“Human gene therapy is one of the fastest-growing areas of medical research, and also one of the most promising,” said WCG Chairman and Chief Executive Officer Donald A. Deieso, Ph.D. “The advances made by scientists and clinicians in the field of gene therapy have enabled us to target disease at the genetic level, redefining the concept of precision medicine.” He added, “More than that, gene transfer researchers have succeeded – over the course of a single lifetime – in transforming the world’s most persistent and lethal viruses into disease-fighting allies in the quest to improve human health.”

Continue reading “WIRB-Copernicus Group Establishes WCG Gene Therapy Advisory Board” »

Mar 27, 2016

Alphabet’s ‘Moonshots’ Head Astro Teller: Fear Of AI And Robots Is Wildly Overblown

Posted by in categories: bioengineering, computing, genetics, robotics/AI

(Photo credit: AP Photo/Jack Plunkett, File)

Astro Teller is tired of the paranoia surrounding artificial intelligence and robotics. The famous computer scientist’s sensitivity around the topic may be understandable considering he bears the brunt of some of that skepticism as the head of X, the Alphabet (and formerly Google) moonshot factory working on many of the company’s futuristic AI and robotics projects.

This past weekend, Teller, whose official title is “captain of moonshots,” took to the stage at the inaugural Silicon Valley Comic Con hoping to dispel some of these misconceptions around AI. His physician wife, Danielle Teller, presented alongside him on some of the fear mongering associated with genetic engineering in humans. After their presentation, the Tellers sat down with FORBES to go deeper on the issue to explain what they hoped to accomplish with their talk.

Continue reading “Alphabet’s ‘Moonshots’ Head Astro Teller: Fear Of AI And Robots Is Wildly Overblown” »

Mar 24, 2016

CRISPR Used to Target RNA in Live Cells For the First Time

Posted by in categories: bioengineering, biotech/medical, genetics, neuroscience

WIKIMEDIA, ROBINSON RCRISPR-a bacterial immune response best known for its genome-editing applications in the lab-has yet again been adapted for scientific purposes, this time to track RNA within cells. Considering the case of synapses — the proteins required for these neural connections are produced from RNAs located at these contacts.

“Just as CRISPR-Cas9 is making genetic engineering accessible to any scientist with access to basic equipment, RNA-targeted Cas9 may support countless other efforts for studying the role of RNA processing in disease or for identifying drugs that reverse defects in RNA processing”, study coauthor David Nelles of the University of California, San Diego, said in a press release. Defective RNA transport is linked to a host of conditions ranging from autism to cancer and researchers need ways to measure RNA movement in order to develop treatments for these conditions. “Our current work focuses on tracking the movement of RNA inside the cell, but future developments could enable researchers to measure other RNA features or advance therapeutic approaches to correct disease-causing RNA behaviors”. But, Gene Yeo, Associate Professor of Cellular and Molecular Medicine at UC San Diego, and his team have applied the technique as a flexible means to targeting RNA in live cells.

Jennifer Doudna, the creator of the CRISPR-Cas9 system for DNA editing, also works out of the University of California research system, and is listed as a co-author for this study. A guide RNA, along with the addition of an oligonucleotide sequence, sent the Cas9 RNA-ward.

Continue reading “CRISPR Used to Target RNA in Live Cells For the First Time” »

Mar 24, 2016

Scientists Build A Live, No-Frills Cell That Could Have A Big Future

Posted by in categories: futurism, genetics

Scientists announced Thursday that they have built a single-celled organism that has just 473 genes — likely close to the minimum number of genes necessary to sustain its life. The development, they say, could eventually lead to new manufacturing methods.

Around 1995, a few top geneticists set out on a quest: to make an organism that had only the genes that were absolutely essential for its survival. A zero-frills life.

It was a heady time.

Continue reading “Scientists Build A Live, No-Frills Cell That Could Have A Big Future” »

Mar 22, 2016

HIV Genes Successfully Edited Out of Immune Cells

Posted by in categories: bioengineering, biotech/medical, genetics

This could have some truly profound implications for the treatment of all viruses, including HIV!


Researchers from Temple University have used the CRISPR/Cas9 gene editing tool to clear out the entire HIV-1 genome from a patient’s infected immune cells. It’s a remarkable achievement that could have profound implications for the treatment of AIDS and other retroviruses.

When we think about CRISPR/Cas9 we tend to think of it as a tool to eliminate heritable genetic diseases, or as a way to introduce new genes altogether. But as this new research shows, it also holds great promise as a means to eliminate viruses that have planted their nefarious genetic codes within host cells. This latest achievement now appears in Nature Scientific Reports.

Continue reading “HIV Genes Successfully Edited Out of Immune Cells” »

Mar 22, 2016

Should You Get Paid For Your DNA?

Posted by in categories: biotech/medical, genetics

Whether people with rare genetic mutations that result in important medical discoveries should be compensated is a topic of intense debate.

Read more